Accumulating evidence suggests that a high tumour burden has a negative effect on
anticancer immunity. The concept of tumour burden, simply defined as the total amount of …

The application of genomic profiling assays using plasma circulating tumor DNA (ctDNA) is
rapidly evolving in the management of patients with advanced solid tumors. Diverse plasma …

Testing peripheral blood for circulating tumor DNA (ctDNA) offers a minimally invasive
opportunity to diagnose, characterize, and monitor the disease in individual cancer patients …

Brain metastases occur commonly in patients with advanced solid malignancies. Yet, less is
known about brain metastases than cancer-related entities of similar incidence. Advances in …

Background Melanoma lacks validated blood-based biomarkers for monitoring and
predicting treatment efficacy. Cell-free circulating tumour DNA (ctDNA) is a promising …

Uveal melanoma (UM) is the most common primary intraocular malignancy affecting adults.
Despite successful local treatment of the primary tumour, metastatic disease develops in up …

Purpose: We evaluated the predictive value of pretreatment ctDNA to inform therapeutic
outcomes in patients with metastatic melanoma relative to type and line of treatment …

Abstract Background Immune checkpoint inhibitors (ICIs) have substantially improved
overall survival in patients with advanced melanoma; however, the lack of biomarkers to …

Targeted kinase inhibitors improve the prognosis of lung cancer patients with ALK
alterations (ALK+). However, due to the emergence of acquired resistance and varied …

Circulating tumor DNA (ctDNA) is a new pan-cancer tumor marker with important
applications for patient prognosis, monitoring progression, and assessing the success of the …